Cargando…

Prevention of vascular calcification by the endogenous chromogranin A-derived mediator that inhibits osteogenic transdifferentiation

The adrenal glands participate in cardiovascular (CV) physiology and the pathophysiology of CV diseases through their effects on sodium and water metabolism, vascular tone and cardiac function. In the present study, we identified a new adrenal compound controlling mesenchymal cell differentiation th...

Descripción completa

Detalles Bibliográficos
Autores principales: Orth-Alampour, Setareh, Gayrard, Nathalie, Salem, Silvia, Bhargava, Shruti, Jankowski, Vera, Jover, Bernard, Notarnicola, Cécile, Noels, Heidi, van der Vorst, Emiel P. C., Kuppe, Christoph, Wolf, Michael, Goettsch, Claudia, Theelen, Wendy, Bruck, Heike, Fliser, Danilo, Loscalzo, Joseph, Wu, Zhuojun, Marx, Nikolaus, Zidek, Walter, Argilés, Àngel, Jankowski, Joachim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8514386/
https://www.ncbi.nlm.nih.gov/pubmed/34647168
http://dx.doi.org/10.1007/s00395-021-00899-z
_version_ 1784583370254057472
author Orth-Alampour, Setareh
Gayrard, Nathalie
Salem, Silvia
Bhargava, Shruti
Jankowski, Vera
Jover, Bernard
Notarnicola, Cécile
Noels, Heidi
van der Vorst, Emiel P. C.
Kuppe, Christoph
Wolf, Michael
Goettsch, Claudia
Theelen, Wendy
Bruck, Heike
Fliser, Danilo
Loscalzo, Joseph
Wu, Zhuojun
Marx, Nikolaus
Zidek, Walter
Argilés, Àngel
Jankowski, Joachim
author_facet Orth-Alampour, Setareh
Gayrard, Nathalie
Salem, Silvia
Bhargava, Shruti
Jankowski, Vera
Jover, Bernard
Notarnicola, Cécile
Noels, Heidi
van der Vorst, Emiel P. C.
Kuppe, Christoph
Wolf, Michael
Goettsch, Claudia
Theelen, Wendy
Bruck, Heike
Fliser, Danilo
Loscalzo, Joseph
Wu, Zhuojun
Marx, Nikolaus
Zidek, Walter
Argilés, Àngel
Jankowski, Joachim
author_sort Orth-Alampour, Setareh
collection PubMed
description The adrenal glands participate in cardiovascular (CV) physiology and the pathophysiology of CV diseases through their effects on sodium and water metabolism, vascular tone and cardiac function. In the present study, we identified a new adrenal compound controlling mesenchymal cell differentiation that regulates osteoblastic differentiation in the context of vascular calcification. This peptide was named the “calcification blocking factor” (CBF) due to its protective effect against vascular calcification and is released from chromogranin A via enzymatic cleavage by calpain 1 and kallikrein. CBF reduced the calcium content of cells and thoracic aortic rings under calcifying culture conditions, as well as in aortas from animals treated with vitamin D and nicotine (VDN animals). Furthermore, CBF prevented vascular smooth muscle cell (VSMC) transdifferentiation into osteoblast-like cells within the vascular wall via the sodium-dependent phosphate transporter PIT-1 and by inhibition of NF-κB activation and the subsequent BMP2/p-SMAD pathway. Pulse pressure, a marker of arterial stiffness, was significantly decreased in VDN animals treated with CBF. In line with our preclinical data, CBF concentration is significantly reduced in diseases characterized by increased calcification, as shown in patients with chronic kidney disease. In preparation for clinical translation, the active site of the native 19-AS long native CBF was identified as EGQEEEED. In conclusion, we have identified the new peptide CBF, which is secreted from the adrenal glands and might prevent vascular calcification by inhibition of osteogenic transdifferentiation. The anti-calcific effects of CBF and short active site may therefore promote the development of new tools for the prevention and/or treatment of vascular calcification. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00395-021-00899-z.
format Online
Article
Text
id pubmed-8514386
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-85143862021-10-27 Prevention of vascular calcification by the endogenous chromogranin A-derived mediator that inhibits osteogenic transdifferentiation Orth-Alampour, Setareh Gayrard, Nathalie Salem, Silvia Bhargava, Shruti Jankowski, Vera Jover, Bernard Notarnicola, Cécile Noels, Heidi van der Vorst, Emiel P. C. Kuppe, Christoph Wolf, Michael Goettsch, Claudia Theelen, Wendy Bruck, Heike Fliser, Danilo Loscalzo, Joseph Wu, Zhuojun Marx, Nikolaus Zidek, Walter Argilés, Àngel Jankowski, Joachim Basic Res Cardiol Original Contribution The adrenal glands participate in cardiovascular (CV) physiology and the pathophysiology of CV diseases through their effects on sodium and water metabolism, vascular tone and cardiac function. In the present study, we identified a new adrenal compound controlling mesenchymal cell differentiation that regulates osteoblastic differentiation in the context of vascular calcification. This peptide was named the “calcification blocking factor” (CBF) due to its protective effect against vascular calcification and is released from chromogranin A via enzymatic cleavage by calpain 1 and kallikrein. CBF reduced the calcium content of cells and thoracic aortic rings under calcifying culture conditions, as well as in aortas from animals treated with vitamin D and nicotine (VDN animals). Furthermore, CBF prevented vascular smooth muscle cell (VSMC) transdifferentiation into osteoblast-like cells within the vascular wall via the sodium-dependent phosphate transporter PIT-1 and by inhibition of NF-κB activation and the subsequent BMP2/p-SMAD pathway. Pulse pressure, a marker of arterial stiffness, was significantly decreased in VDN animals treated with CBF. In line with our preclinical data, CBF concentration is significantly reduced in diseases characterized by increased calcification, as shown in patients with chronic kidney disease. In preparation for clinical translation, the active site of the native 19-AS long native CBF was identified as EGQEEEED. In conclusion, we have identified the new peptide CBF, which is secreted from the adrenal glands and might prevent vascular calcification by inhibition of osteogenic transdifferentiation. The anti-calcific effects of CBF and short active site may therefore promote the development of new tools for the prevention and/or treatment of vascular calcification. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00395-021-00899-z. Springer Berlin Heidelberg 2021-10-13 2021 /pmc/articles/PMC8514386/ /pubmed/34647168 http://dx.doi.org/10.1007/s00395-021-00899-z Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Contribution
Orth-Alampour, Setareh
Gayrard, Nathalie
Salem, Silvia
Bhargava, Shruti
Jankowski, Vera
Jover, Bernard
Notarnicola, Cécile
Noels, Heidi
van der Vorst, Emiel P. C.
Kuppe, Christoph
Wolf, Michael
Goettsch, Claudia
Theelen, Wendy
Bruck, Heike
Fliser, Danilo
Loscalzo, Joseph
Wu, Zhuojun
Marx, Nikolaus
Zidek, Walter
Argilés, Àngel
Jankowski, Joachim
Prevention of vascular calcification by the endogenous chromogranin A-derived mediator that inhibits osteogenic transdifferentiation
title Prevention of vascular calcification by the endogenous chromogranin A-derived mediator that inhibits osteogenic transdifferentiation
title_full Prevention of vascular calcification by the endogenous chromogranin A-derived mediator that inhibits osteogenic transdifferentiation
title_fullStr Prevention of vascular calcification by the endogenous chromogranin A-derived mediator that inhibits osteogenic transdifferentiation
title_full_unstemmed Prevention of vascular calcification by the endogenous chromogranin A-derived mediator that inhibits osteogenic transdifferentiation
title_short Prevention of vascular calcification by the endogenous chromogranin A-derived mediator that inhibits osteogenic transdifferentiation
title_sort prevention of vascular calcification by the endogenous chromogranin a-derived mediator that inhibits osteogenic transdifferentiation
topic Original Contribution
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8514386/
https://www.ncbi.nlm.nih.gov/pubmed/34647168
http://dx.doi.org/10.1007/s00395-021-00899-z
work_keys_str_mv AT orthalampoursetareh preventionofvascularcalcificationbytheendogenouschromograninaderivedmediatorthatinhibitsosteogenictransdifferentiation
AT gayrardnathalie preventionofvascularcalcificationbytheendogenouschromograninaderivedmediatorthatinhibitsosteogenictransdifferentiation
AT salemsilvia preventionofvascularcalcificationbytheendogenouschromograninaderivedmediatorthatinhibitsosteogenictransdifferentiation
AT bhargavashruti preventionofvascularcalcificationbytheendogenouschromograninaderivedmediatorthatinhibitsosteogenictransdifferentiation
AT jankowskivera preventionofvascularcalcificationbytheendogenouschromograninaderivedmediatorthatinhibitsosteogenictransdifferentiation
AT joverbernard preventionofvascularcalcificationbytheendogenouschromograninaderivedmediatorthatinhibitsosteogenictransdifferentiation
AT notarnicolacecile preventionofvascularcalcificationbytheendogenouschromograninaderivedmediatorthatinhibitsosteogenictransdifferentiation
AT noelsheidi preventionofvascularcalcificationbytheendogenouschromograninaderivedmediatorthatinhibitsosteogenictransdifferentiation
AT vandervorstemielpc preventionofvascularcalcificationbytheendogenouschromograninaderivedmediatorthatinhibitsosteogenictransdifferentiation
AT kuppechristoph preventionofvascularcalcificationbytheendogenouschromograninaderivedmediatorthatinhibitsosteogenictransdifferentiation
AT wolfmichael preventionofvascularcalcificationbytheendogenouschromograninaderivedmediatorthatinhibitsosteogenictransdifferentiation
AT goettschclaudia preventionofvascularcalcificationbytheendogenouschromograninaderivedmediatorthatinhibitsosteogenictransdifferentiation
AT theelenwendy preventionofvascularcalcificationbytheendogenouschromograninaderivedmediatorthatinhibitsosteogenictransdifferentiation
AT bruckheike preventionofvascularcalcificationbytheendogenouschromograninaderivedmediatorthatinhibitsosteogenictransdifferentiation
AT fliserdanilo preventionofvascularcalcificationbytheendogenouschromograninaderivedmediatorthatinhibitsosteogenictransdifferentiation
AT loscalzojoseph preventionofvascularcalcificationbytheendogenouschromograninaderivedmediatorthatinhibitsosteogenictransdifferentiation
AT wuzhuojun preventionofvascularcalcificationbytheendogenouschromograninaderivedmediatorthatinhibitsosteogenictransdifferentiation
AT marxnikolaus preventionofvascularcalcificationbytheendogenouschromograninaderivedmediatorthatinhibitsosteogenictransdifferentiation
AT zidekwalter preventionofvascularcalcificationbytheendogenouschromograninaderivedmediatorthatinhibitsosteogenictransdifferentiation
AT argilesangel preventionofvascularcalcificationbytheendogenouschromograninaderivedmediatorthatinhibitsosteogenictransdifferentiation
AT jankowskijoachim preventionofvascularcalcificationbytheendogenouschromograninaderivedmediatorthatinhibitsosteogenictransdifferentiation